|1.||Kumar, R: 3 articles (10/2001 - 01/2000)|
|2.||Yang, Chengfeng: 2 articles (02/2008 - 02/2006)|
|3.||Kazanietz, Marcelo G: 2 articles (02/2008 - 02/2006)|
|4.||Talukder, A H: 2 articles (01/2000 - 01/2000)|
|5.||Sollome, James J: 1 article (01/2014)|
|6.||Vaillancourt, Richard R: 1 article (01/2014)|
|7.||Camenisch, Todd D: 1 article (01/2014)|
|8.||Thavathiru, Elangovan: 1 article (01/2014)|
|9.||Fang, Xiaohong: 1 article (10/2009)|
|10.||Shi, Xiaoli: 1 article (10/2009)|
|1.||Breast Neoplasms (Breast Cancer)
05/15/2007 - "First, treatment of T47D breast cancer cells with heregulin beta1 results in a two-fold increase in nuclear BRCA1 as assessed by FACS analysis, immunoblotting and immunofluorescence. "
01/01/2007 - "This may have implications for the effectiveness of anti-EGFR therapies in breast cancer as HRGbeta1 is enriched in many EGFR-positive breast tumours."
02/15/2008 - "Heregulin beta1 promotes breast cancer cell proliferation through Rac/ERK-dependent induction of cyclin D1 and p21Cip1."
01/01/2007 - "The effects of HRGbeta1 on gefitinib-treated Tam-R cell growth and invasion were also examined, and HRGbeta1 expression levels were assessed in breast cancer tissue by immunohistochemistry to address the potential clinical relevance of such a resistance mechanism. "
01/01/2002 - "Comparison of the characteristic of estrogenic action patterns of beta-HCH and heregulin beta1 in MCF-7 human breast cancer cells."
08/20/2002 - "This is the first demonstration of the ability of HRGbeta1 to activate STATs in mammary tumor cells. "
10/01/2009 - "Heregulin beta1 (HRG), the specific ligand of HER3, was used for HER2 activation as HER3 is the preferable dimerization partner of HER2 and HER3/HER2 is the most representative heterodimer found in cancer. "
07/20/2000 - "We demonstrate that heregulin beta1 induces VEGF secretion in most cancer cell lines, while no significant effect was observed in normal human mammary and bronchial primary cells. "
10/01/2007 - "Catenin dissociation from VE-cadherin was enhanced by Heregulin beta1 (P < .05) stimulation and decreased by trastuzumab (P < .05) blockade of HER2 signaling in cancer cells. "
09/29/2005 - "We show that HSP elevation in tumor cells can be induced by the highly malignant factor heregulin beta1 (HRGbeta1), which induces HSP expression through heat shock transcription factor 1 (HSF1). "
09/01/1998 - "We conclude that 17beta-estradiol and HRGbeta1, in combination, potently inhibit cell proliferation of three ER negative breast carcinoma cell lines."
09/01/1998 - "Inhibition of cell proliferation by 17beta-estradiol and heregulin beta1 in estrogen receptor negative human breast carcinoma cell lines."
03/03/1998 - "As a step in the design of directed toxins, aimed at cells that overexpress HER receptors, particularly breast carcinoma cells, we studied the properties of a chimera of diphtheria toxin (DT) and heregulin beta1. "
06/01/1999 - "SKOV-3, NIH:OVCAR-3, NIH:OVCAR-8, Ovca 429 and Ovca 433 ovarian carcinoma cell lines were examined to correlate biological behavior (growth in monolayer and soft agar) with erbB family receptor expression levels and response to recombinant Heregulin beta1 (Hrg). "
11/01/1998 - "In TNF-sensitive breast and cervical carcinoma cells activation of EGFR or ErbB2 by the exogenous growth factors EGF and heregulin beta1 resulted in a significant increase in the number of cells surviving TNF-alpha treatment. "
|4.||Ovarian Neoplasms (Ovarian Cancer)
|5.||Neoplasm Metastasis (Metastasis)
|2.||Epidermal Growth Factor Receptor (EGF Receptor)
|4.||Epidermal Growth Factor (EGF)
|5.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|6.||Transforming Growth Factor alpha (TGF-alpha)
|9.||Intercellular Signaling Peptides and Proteins (Growth Factors)
|10.||Neuregulin-1 (Neuregulin 1)